Relvar Ellipta® - new molecule in a new delivery system - new horizons in the treatment of bronchial asthma

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract


Bronchial asthma is a serious socio-economic problem despite of the availability of highly effective therapy for control of symptoms. The gold standard of asthma therapy is high effective and safe combination of ICS+LABA. However, even use of these drugs leave more than half of patients around the world without full control over the symptoms of the disease. This leads for necessity of the search of new therapies - molecules as new drugs and new means for delivery, allowing to minimize technical errors during the inhalation manoeuvre, improving patient treatment adherence. This drug is Relvar Ellipta® containing a combination of new molecules of ICS and LABA in a new, improved delivery system for use 1 time per day.

Full Text

Restricted Access

About the authors

E V Nazarova

Institute of Immunology


E A Latysheva

Institute of Immunology

Email: ealat@mail.ru

References

  1. Asthma. Quick asthma facts and The Faces of asthma. Geneva: World Health Organization; 2010. Available from: http://www. who.int/respiratory/asthma/en/.
  2. Cochrane G.M. Compliance and outcomes in patients with asthma. Drugs. 1996, v. 52, p. 12-19.
  3. Национальная программа «Бронхиальная астма у детей. Стратегия лечения и профилактики». М., 1997, с. 93.
  4. Белевский А.С., Булкина Л.С., Княжеская Н.П. Обучение больных бронхиальной астмой. Бронхиальная астма. Под ред. А.Г. Чучалина. М., 1997, № 2, с. 375-393.
  5. Chmelik F., Doughty A. Objective measurement of compliance in asthma treatment. Ann. Allergy. 1994, v. 73, р. 527-532.
  6. Глобальная стратегия лечения и профилактики бронхиальной астмы. Пересмотр 2015 г. www.ginaasthma.org.
  7. American Thoracic Society. Proceedings of the ATS workshop on refractory asthma. Current understanding, recommendations, and unanswered questions. Am. J. Respir. Crit. Care Med. 2000, No. 162, р. 2341-2351.
  8. Клиническая аллергология. Под ред. Р.М. Хаитова.
  9. Bateman E.D., Bousquet J., Braunstein G.L. Is overall asthma controlbeing achieved? A hypotesis-generating study. Eur. Respir. J. 2001, v. 17, p. 589-595.
  10. Mitchel C., Jenkins C., Scicchitano R., Rubenfeld A., Kottakis J. Formoterol (Foradil) and medium-high doses of inhaled corticosteroids are more effective than high doses of corticosteroids in moderate-to-severe asthma. Pulmonary pharmacology and Therapeutics. 2003, No. 16, p. 299-306.
  11. Barnes P. J. Clinical outcome of adding long-acting β-agonists to inhaled corticosteroids. Respir. Med. 2001, v. 95, p. 12-16.
  12. Bowler S. Inhaled steroids in asthma. Should the dose be redused? Aus. Fam. Physic. 2002, v. 31, p. 746.
  13. Цой А.Н. Фиксированная комбинация ультрамелкодисперсных дозированных аэрозолей беклометазона дипропионата/формотерола: слагаемые успеха. Приложение к журналу Consilium medicum. «Пульмонология». 2008, c. 39-45.
  14. Biggadike K., Bledsoe R.K., Hassell A.M. et all. X-ray crystal structure of the novel enhanced-affinity glucocorticoid agonist fluticasone furoate in the glucocorticoid receptor-ligand binding domain. J. Med. Chem. 2008, v. 51, p. 3349-3352.
  15. Mark Salter, Keith Biggadike, Joyce L. et al. Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. Am. J. Physiol. Lung. Cell Mol. Physiol. 2007, v. 293, p. 660-667.
  16. Valotis A., Högger P. Human receptor kinetics and tissue affinity of the enhanced affinity glucocorticoid GW685698X (Abstract). XXV Congress Eur. Acad. Allergol Clin. Immunol. Vienna, Austria. 2006, v. 10-14, 780 p.
  17. Valotis A., Högger P. Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoate. Respir. Res. 2007, v. 25, p. 54.
  18. Man Y., Hart V.J., Ring C.J. et al. Loss of epithelial integrity resulting from E-cadherin dysfunction predisposes airway epithelial cells to adenoviral infection. Am. J. Respir. Cell Mol. Biol. 2000, v. 23, p. 610-617.
  19. Rossios C., To Y., To M. et al. Long-acting fluticasone furoate has a superior pharmacological profile to fluticasone propionate in human respiratory cells. Eur. J. Pharmacol. 2011, v. 16, p. 244-251.
  20. Cazzola M., Page C.P., Calzetta L., Matera M.G. Pharmacology and therapeutics of bronchodilators. Pharmacol. Rev. 2012, v. 64, p. 450-504.
  21. Procopiou P.A., Barrett V.J., Bevan N.J. et al. Synthesis and structure-activity relationships of long-acting β2-adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach. J. Med. Chem. 2010, v. 53, p. 4522-4530.
  22. Slack R.J., Barrett V.J., Morrison V.S. et al. In vitro pharmacological characterization of vilanterol, a novel long acting ß2-adrenoceptor agonist with 24-hour duration of action. J. Pharmacol. Exp. Ther. 2013, v. 344, p. 218-230.
  23. Lötvall J., Bateman E.D., Bleecker E.R. et al. 24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroids. Eur. Respir. J. 2012, v. 40, p. 570-579.
  24. Sterling R., Lim J., Frith L. et al. Efficacy and optimal dosing interval of the long-acting b2-agonist, vilanterol, in persistent asthma: a randomised trial. Respir. Med. 2012, v. 106, p. 1110-1115.
  25. Fanta C.H. Drug therapy: asthma. N. Engl. J. Med. 2009, v. 360, p. 1002-1014.
  26. Bateman E.D., Bleecker E.R., Lötvall J. et al. Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial. Respir. Med. 2012, v. 106, p. 642-650.
  27. Bleecker E.R., Bateman E.D., Busse W.W. et al. Once-daily fluticasone furoate is efficacious in patients with symptomatic asthma on low-dose inhaled corticosteroids. Ann. Allergy Asthma Immunol. 2012, v. 109, p. 353-358.
  28. Busse W.W., Bleecker E.R., Bateman E.D. et al. Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial. Thorax. 2012, v. 67, p. 35-41.
  29. Lötvall J., Bateman E.D., Bleecker E.R. et al. 24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroids. Eur. Respir. J. 2012, v. 40, p. 570-579.
  30. Sharma N. et al. Operability Of The Ellipta™ Dry Powder Inhaler: A Comparative Evaluation Of Handling Technique In Inhalation Therapy-Naïve Subjects. Am. J. Respir. Crit. Care Med. 2014, v. 189, p. 56-93.
  31. Prime D., de Backer W., Hamilton M. et al. Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler. J. Aerosol Med. Pulm. Drug. Deliv. 2015, v. 15.
  32. Svedsater H., Jacques L., Goldfrad C., Bleecker E.R. Ease of use of the ELLIPTA dry powder inhaler: data from three randomized controlled trials in patients with asthma. NPJ Prim. Care Respir. Med. 2014, v. 26, p. 14019.
  33. ClinicalTrials.gov Study HZA106827: Efficacy/safety study of fluticasone furoate/vilanterol in adult and adolescent asthmatics. GlaxoSmithKline.
  34. Busse W.W., O’Byrne P.M., Bleecker E.R. et al. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the b2-agonist vilanterol administered once daily for 52 weeks in patients >ј12 years old with asthma: a randomised trial. Thorax. 2013, v. 68, p. 513-520.
  35. Bleecker, Lötvall, O’Byrne P. et al. Fluticasone Furoatee Vilanterol 100/25 mcg Compared with Fluticasone Furoate 100 mcg in Asthma: A Randomized Trial. J. Allergy Clin. Immunol. Pract. 2014, v. 2, p. 553-561.
  36. Bernstein D.I., Bateman E.D., Woodcock A. et al. Fluticasone furoate (FF)/vilanterol (100/25 mcg or 200/25 mcg) or FF (100 mcg) in persistent asthma. J. Asthma. 2015, v. 19, p. 1-11

Statistics

Views

Abstract - 18

PDF (Russian) - 0

PlumX

Article Metrics

Metrics Loading ...

Dimensions


Copyright (c) 2015 Russian Allergological Journal

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies